At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Nov 9, 2026 at 07:00 ET
Hemab Therapeutics announced the initiation of SOLARA, a pivotal Phase 3 trial of sutacimig (HMB-001) for prophylactic treatment of Glanzmann thrombasthenia, a rare bleeding disorder with no approved prophylactic therapy. The single-arm, intra-participant controlled trial will enroll ~75 participants, with a 24-week run-in followed by 48 weeks of treatment. The FDA recommended a randomized design but acknowledged feasibility concerns; Hemab proceeded with a single-arm design. The trial builds on Phase 2 data showing a 62% reduction in high-intensity annualized treated bleed rates.
- First participants consented for SOLARA Phase 3 trial of sutacimig in Glanzmann thrombasthenia (GT)
- Single-arm, open-label trial with 24-week run-in and 48-week treatment; primary endpoint is annualized treated bleed rate
- Phase 2 data showed 62% reduction in mean high-intensity annualized treated bleed rate and 92% of participants had reduced treated bleed rates
- FDA granted Fast Track, Orphan Drug, and Breakthrough Therapy Designations for sutacimig in GT
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access